Amgen Inc.



$176.26Share Price
$129.2 BMarket Cap
7.8%EBIT / EV
8.5%FCF / EV
32.2%Cash ROIC
6.7%3yr Avg Revenue Growth
6.07Current Ratio
star logo

Business Model Diligence

We do not yet have Business Model Diligence for this stock.

Statistical Diligence

check mark The EBIT / Enterprise Value of 7.8% ranks as Above Average.
check mark The Free Cash Flow / Enterprise Value of 8.5% ranks as Very High.
check mark The Return on Invested Capital Value of 29.4% ranks as Very High.
check mark The Cash Return on Capital Value of 32.2% ranks as Very High.
check mark The 3 Year Average Revenue Growth Value of 6.7% ranks as Average.
check mark Near-term Financial Health appears to be Very Good. The Current Ratio is 6.07.

Company Description

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. Its products include aranesp, blincyto, corlanor, enbrel, epogen, imlygic, kyprolis, neulasta, neupogen, nplate, parsab, prolia, repatha, sensipar, vectibix, and xgeva. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.


You must have a MagicDiligence Membership to view the Calculations for this stock. If you are already a member, you need to log in first.